- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 231/14
Total number of patents in this class: 1155
10-year publication summary
92
|
63
|
84
|
69
|
62
|
64
|
72
|
57
|
46
|
28
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bayer Cropscience AG | 2040 |
64 |
Syngenta Participations AG | 1904 |
50 |
Theravance Biopharma R&D IP, LLC | 456 |
49 |
BASF SE | 20940 |
35 |
Syngenta Crop Protection AG | 6074 |
22 |
BioCryst Pharmaceuticals, Inc. | 174 |
22 |
Takeda Pharmaceutical Company Limited | 2708 |
19 |
Orion Corporation | 670 |
19 |
Syngenta Limited | 454 |
16 |
Sumitomo Chemical Company, Limited | 9043 |
16 |
Activesite Pharmaceuticals, Inc. | 19 |
16 |
KalVista Pharmaceuticals Limited | 113 |
15 |
AstraZeneca AB | 2892 |
12 |
Solvay SA | 987 |
12 |
sanofi-aventis | 363 |
12 |
F. Hoffmann-La Roche AG | 7947 |
11 |
Dow AgroSciences LLC | 1223 |
11 |
Rezolute, Inc. | 32 |
11 |
Hoffmann-La Roche Inc. | 3439 |
10 |
Bayer Intellectual Property GmbH | 2498 |
10 |
Other owners | 723 |